Kolon Life Science said it made a strategic MOU with Korea Tour Promotion Agency (KTPA) Wednesday to attract foreign patients by making the most of Invossa K Inj, the world’s first gene therapy for osteoarthritis.
Kolon will provide medical advice about Invossa, and the agency will set up a one-stop system for promotion and marketing for foreign countries, the attraction of foreign patients, and direct connection with Korean hospitals, under the MOU.
|Lee Woo-sok이우석, CEO of Kolon Life Science코오롱생명과학 (left), and at KTPA Chairman Joo Cheon-gi주천기 signed an MOU Wednesday to make the most of Invossa K to attract foreign patients.|
International patients can get various information about the effects of Invossa as well as convenient services, such as consultation about treatments, through the one-stop system. They will also get medical checkup and treatments from Korean doctors after visiting Korea.
“Korea will publicize its superior technology and create added values in medical tourism area by making close connection with foreign medical institutions through the world’s first osteoarthritis therapy Invossa,“ KPTA Chairman Joo said.
A Kolon executive also expressed high expectations for the project.
“We are doing marketing with foreign partners for Invossa, including Mundi Pharma먼디파마, and Mitsubishi Tanabe Pharma. We have a good chance to let foreign patients know the real effectiveness of Invossa by making the MOU,” CEO Lee said. “The overseas promotion and marketing will be the beginning of the experience and to set up a network for Invossa closer to new global drugs.”
<© Korea Biomedical Review, All rights reserved.>